🟢 Summit Therapeutics is trading 4.5% up in pre-market after statistically significant HARMONi progression-free-survival improvement

Summit Therapeutics is trading 4.5% up in pre-market at $13.96 after reporting statistically significant progression-free-survival improvement from ivonescimab plus chemotherapy in previously treated EGFR-mutated advanced lung cancer.

• August 25, 2026 HARMONi results showed median progression-free survival of 6.8 months versus 4.4 months for placebo plus chemotherapy.
• Hazard ratio was 0.52, with p<0.0001.
• The catalyst remains company-specific and clinically material.